159 related articles for article (PubMed ID: 35504427)
41. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation.
Weiss CK; Kohnle MV; Landfester K; Hauk T; Fischer D; Schmitz-Wienke J; Mailänder V
ChemMedChem; 2008 Sep; 3(9):1395-403. PubMed ID: 18613205
[TBL] [Abstract][Full Text] [Related]
42. Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer.
Ahmad N; Alam MA; Ahmad R; Naqvi AA; Ahmad FJ
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):432-446. PubMed ID: 28503995
[TBL] [Abstract][Full Text] [Related]
43. Cholesterol-PEG comodified poly (N-butyl) cyanoacrylate nanoparticles for brain delivery: in vitro and in vivo evaluations.
Hu X; Yang F; Liao Y; Li L; Zhang L
Drug Deliv; 2017 Nov; 24(1):121-132. PubMed ID: 28156159
[TBL] [Abstract][Full Text] [Related]
44. Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles.
Vilella A; Ruozi B; Belletti D; Pederzoli F; Galliani M; Semeghini V; Forni F; Zoli M; Vandelli MA; Tosi G
Pharmaceutics; 2015 Jun; 7(2):74-89. PubMed ID: 26102358
[TBL] [Abstract][Full Text] [Related]
45. Anti-proliferate and apoptosis triggering potential of methotrexate-transferrin conjugate encapsulated PLGA nanoparticles with enhanced cellular uptake by high-affinity folate receptors.
Parmar A; Jain A; Uppal S; Mehta SK; Kaur K; Singh B; Sandhir R; Sharma S
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):704-719. PubMed ID: 29745729
[TBL] [Abstract][Full Text] [Related]
46. Development of zolmitriptan loaded PLGA/poloxamer nanoparticles for migraine using quality by design approach.
Girotra P; Singh SK; Kumar G
Int J Biol Macromol; 2016 Apr; 85():92-101. PubMed ID: 26724690
[TBL] [Abstract][Full Text] [Related]
47. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
Schroeder U; Sommerfeld P; Ulrich S; Sabel BA
J Pharm Sci; 1998 Nov; 87(11):1305-7. PubMed ID: 9811481
[TBL] [Abstract][Full Text] [Related]
48. Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy.
Martins C; Araújo F; Gomes MJ; Fernandes C; Nunes R; Li W; Santos HA; Borges F; Sarmento B
Eur J Pharm Biopharm; 2019 May; 138():111-124. PubMed ID: 29397261
[TBL] [Abstract][Full Text] [Related]
49. Poloxamer 188 as surfactant in biological formulations - An alternative for polysorbate 20/80?
Bollenbach L; Buske J; Mäder K; Garidel P
Int J Pharm; 2022 May; 620():121706. PubMed ID: 35367584
[TBL] [Abstract][Full Text] [Related]
50. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
[TBL] [Abstract][Full Text] [Related]
51. Polysorbate 80 coated chitosan nanoparticles for delivery of α-melanocyte stimulating hormone analog (NDP-MSH) to the brain reverse cognitive impairment related to neuroinflammation produced by a high-fat diet (HFD).
Herrera G; Scimonelli T; Lasaga M; Granero G; Onnainty R
Neuropharmacology; 2024 Aug; 253():109969. PubMed ID: 38688422
[TBL] [Abstract][Full Text] [Related]
52. Lipid-PLGA hybrid nanoparticles of paclitaxel: Preparation, characterization, in vitro and in vivo evaluation.
Godara S; Lather V; Kirthanashri SV; Awasthi R; Pandita D
Mater Sci Eng C Mater Biol Appl; 2020 Apr; 109():110576. PubMed ID: 32228957
[TBL] [Abstract][Full Text] [Related]
53. Influence of nanoparticle size on blood-brain barrier penetration and the accumulation of anti-seizure medicines in the brain.
Meng Q; Meng H; Pan Y; Liu J; Li J; Qi Y; Huang Y
J Mater Chem B; 2022 Jan; 10(2):271-281. PubMed ID: 34897348
[TBL] [Abstract][Full Text] [Related]
54. Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies.
Jose S; Juna BC; Cinu TA; Jyoti H; Aleykutty NA
Colloids Surf B Biointerfaces; 2016 Jun; 142():307-314. PubMed ID: 26970818
[TBL] [Abstract][Full Text] [Related]
55. Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.
Guedj AS; Kell AJ; Barnes M; Stals S; Gonçalves D; Girard D; Lavigne C
Int J Nanomedicine; 2015; 10():5965-79. PubMed ID: 26445538
[TBL] [Abstract][Full Text] [Related]
56. Time-Dependent Internalization of Polymer-Coated Silica Nanoparticles in Brain Endothelial Cells and Morphological and Functional Effects on the Blood-Brain Barrier.
Bittner A; Gosselet F; Sevin E; Dehouck L; Ducray AD; Gaschen V; Stoffel MH; Cho H; Mevissen M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562136
[TBL] [Abstract][Full Text] [Related]
57. Lecithin coating as universal stabilization and functionalization strategy for nanosized drug carriers to overcome the blood-brain barrier.
Wünsch A; Mulac D; Langer K
Int J Pharm; 2021 Jan; 593():120146. PubMed ID: 33279714
[TBL] [Abstract][Full Text] [Related]
58. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
Fornaguera C; Dols-Perez A; Calderó G; García-Celma MJ; Camarasa J; Solans C
J Control Release; 2015 Aug; 211():134-43. PubMed ID: 26057857
[TBL] [Abstract][Full Text] [Related]
59. Copper transport mediated by nanocarrier systems in a blood-brain barrier in vitro model.
Fehse S; Nowag S; Quadir M; Kim KS; Haag R; Multhaup G
Biomacromolecules; 2014 May; 15(5):1910-9. PubMed ID: 24725062
[TBL] [Abstract][Full Text] [Related]
60. Vitamin E-Oligo(methyl diglycol l-glutamate) as a Biocompatible and Functional Surfactant for Facile Preparation of Active Tumor-Targeting PLGA Nanoparticles.
Wu J; Zhang J; Deng C; Meng F; Zhong Z
Biomacromolecules; 2016 Jul; 17(7):2367-74. PubMed ID: 27305935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
